ARQT News and Press, Arcutis Biotherapeutics Inc.

2024-07-09 17:14:02 ET More on Arcutis Biotherapeutics Arcutis Stock: Sales Expansion Momentum Puts It On A Good Trajectory Arcutis Biotherapeutics, Inc. (ARQT) Q1 2024 Earnings Call Transcript Arcutis Biotherapeutics: Betting Big On Zoryve Arcutis says FDA s...

ZORYVE cream provides rapid relief, with efficacy, safety, and tolerability demonstrated up to 56 weeks of treatment ZORYVE cream rapidly and significantly reduces itch, the most bothersome symptom of atopic dermatitis (AD) Once-daily cream is for use anywhere on the body for any duration...

2024-07-09 11:12:36 ET More on Arcutis Biotherapeutics Arcutis Stock: Sales Expansion Momentum Puts It On A Good Trajectory Arcutis Biotherapeutics, Inc. (ARQT) Q1 2024 Earnings Call Transcript Arcutis Biotherapeutics: Betting Big On Zoryve Arcutis Biotherape...

WESTLAKE VILLAGE, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that the Company has been in communication with the U....

2024-07-03 13:34:14 ET Mizhuo picks Axsome Therapeutics ( AXSM ), Wave Life Sciences ( WVE ), Arcutis Biotherapeutics ( ARQT ), LivaNova ( LIVN ) and Humana ( HUM ) as July’s top picks.... Read the full article on Seeking Alpha For further details see:...

2024-06-16 18:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-06-13 06:00:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Investors with any experience in the world of penny stocks know that risk is real. That risk is higher as the price of shares goes lower. Thus, stocks trading between $5 and $10 are somewha...

Investigational roflumilast cream 0.15% showed continued improvements in the signs and symptoms of AD, including itch, through 56 weeks of treatment 66.2% of participants treated with once-daily roflumilast cream 0.15% in both the 4-week parent study and the 52-week open label extension ach...

New long-term safety and efficacy data of investigational roflumilast cream 0.15% in mild to moderate atopic dermatitis will be presented in an oral session Preclinical data on ARQ-234, CD200R agonist, for the treatment of atopic dermatitis Additional presentation of the consistent tole...

WESTLAKE VILLAGE, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will participate in the Goldman Sa...